^
Association details:
| Biomarker: | PD-L1 expression + BRAF negative |
|---|---|
| Cancer: | Thyroid Gland Anaplastic Carcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5PSQ-158 Off-label use of pembrolizumab in PD-L1 positive metastatic anaplastic thyroid carcinoma: a case report
Excerpt:
To describe the clinical case of a 38-year-old man with BRAF negative and PD-L1 positive metastatic ATC, treated with pembrolizumab….After 3 months from the start of pembrolizumab and after 14 weeks from the start of lenvatinib, a reduction in thyroglobulin was detected (4906 ng/mL) and the results of vertebral MR and mandibular CT showed a reduction in metastases....Pembrolizumab combined with lenvatinib seemed to be effective in treating metastatic ATC and could become a therapeutic choice for patients presenting with PD-L1 expression.
DOI:
http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.277
